What one share of Pharmacyte Biotech holds
The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC,
Pharmacyte Biotech’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Sales | $0.00 |
|---|---|
| Profit | −$2.20 |
| Cash and investments | $1.66 |
| Book value | $2.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$4.23 | — | — | — | $4.66 |
| 2021 | $0.00 | −$2.45 | — | — | — | $4.20 |
| 2022 | $0.00 | −$0.27 | — | — | — | $4.34 |
| 2023 | $0.00 | −$0.22 | — | — | — | $4.33 |
| 2024 | $0.00 | −$1.80 | — | — | — | $3.44 |
| 2025 | $0.00 | $3.19 | — | — | — | $7.64 |
| 2026 | $0.00 | −$2.77 | — | — | — | $3.10 |
Common questions about Pharmacyte Biotech
How much does one share of Pharmacyte Biotech earn?
Over the last 12 months, Pharmacyte Biotech lost $2.20 for each share.
Does Pharmacyte Biotech pay a dividend?
Pharmacyte Biotech didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Pharmacyte Biotech’s book value per share?
Pharmacyte Biotech’s book value is $2.56 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of July 31, 2026.
How much cash and debt does each share of Pharmacyte Biotech have?
Each share of Pharmacyte Biotech has $1.66 of cash and investments, as of July 31, 2026.
Has Pharmacyte Biotech bought back shares?
Pharmacyte Biotech’s share count rose about 827% from 2020 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.